NASDAQ:MRSN - Mersana Therapeutics Stock Price, Forecast & News

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Mersana Therapeutics Inc (NASDAQ:MRSN) announced its earnings results on Wednesday, November, 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.02. The company earned $0.84 million during the quarter, compared to analysts' expectations of $0.50 million. Mersana Therapeutics had a negative net margin of 79.49% and a negative return on equity of 41.14%. View Mersana Therapeutics' Earnings History.

Mersana Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Mersana Therapeutics.

4 equities research analysts have issued 1-year price targets for Mersana Therapeutics' stock. Their forecasts range from $12.00 to $12.00. On average, they anticipate Mersana Therapeutics' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 31.0% from the stock's current price. View Analyst Price Targets for Mersana Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mersana Therapeutics.

News stories about MRSN stock have been trending extremely positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Mersana Therapeutics earned a news sentiment score of 5.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Mersana Therapeutics.

Mersana Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,800,000 shares, an increase of 68.2% from the January 15th total of 1,070,000 shares. Based on an average daily volume of 385,200 shares, the short-interest ratio is currently 4.7 days. Currently, 5.6% of the company's shares are short sold. View Mersana Therapeutics' Current Options Chain.

Some companies that are related to Mersana Therapeutics include Nabriva Therapeutics (NBRV), Amneal Pharmaceuticals (AMRX), Madrigal Pharmaceuticals (MDGL), Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Endo International (ENDP), Dicerna Pharmaceuticals (DRNA), Zogenix (ZGNX), IGM Biosciences (IGMS), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Rocket Pharmaceuticals (RCKT), Supernus Pharmaceuticals (SUPN), Athenex (ATNX) and Revance Therapeutics (RVNC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include Agile Therapeutics (AGRX), Nabriva Therapeutics (NBRV), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Eyepoint Pharmaceuticals (EYPT), Fortress Biotech (FBIO), Marinus Pharmaceuticals (MRNS), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP) and Dynavax Technologies (DVAX).

(MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include BVF Inc. IL (2.47%), Renaissance Technologies LLC (1.50%), State Street Corp (1.30%), Oxford Asset Management LLP (0.42%), Bank of New York Mellon Corp (0.41%) and Point72 Asset Management L.P. (0.31%). Company insiders that own Mersana Therapeutics stock include Enterprise Associates 14 New and Timothy B Lowinger. View Institutional Ownership Trends for Mersana Therapeutics.

MRSN stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Point72 Asset Management L.P., Panagora Asset Management Inc., Renaissance Technologies LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Mersana Therapeutics.

MRSN stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Assenagon Asset Management S.A., Acadian Asset Management LLC, California Public Employees Retirement System, Oxford Asset Management LLP, Quantitative Systematic Strategies LLC, State Street Corp and UBS Group AG. View Insider Buying and Selling for Mersana Therapeutics.

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MRSN stock can currently be purchased for approximately $9.16.

Mersana Therapeutics has a market capitalization of $438.58 million and generates $10.59 million in revenue each year. The company earns $-64,260,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe.View Additional Information About Mersana Therapeutics.

The official website for Mersana Therapeutics is http://www.mersana.com/.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]